BLTE Company Profile and Key Details

Belite Bio, Inc has 32.83 million shares outstanding. The public float is 15.17 million shares, elevated short interest at 1.18% of float. This equals 180.33 thousand shares. The short ratio is 3.89 days. Institutional investors hold 1.6% of the float. Insiders own 53.45%.

BLTE has shown sold momentum, gaining 3.37% over the past week and 82.43% over the past quarter, though year-to-date performance is up 0.03%. Short-term trend indicators are bearishly aligned (SMA20 4.9%, SMA50 13.15%, SMA200 85.16%). The stock’s 14-day RSI is 64.81 (firm momentum), while the ATR of 8.67 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -5.72% below its high and over 284.8% above its low. Average 10-day trading volume of 252.03 thousand shares is in line with the 3-month average of 230.67 thousand, indicating normal recent market interest.

Belite Bio, Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.02. This means the shares are trading above this model’s fair value.

Belite Bio, Inc generated EPS of -$1.92 over the past year. Five-year average earnings growth is -777.09%. The latest quarter delivered EPS of -$0.65. The next quarter is forecast at -$0.55. Next year's EPS is expected at $43.48. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 9 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $266.00 to $80.00. The high target offers 58.45% upside. The low target suggests -52.35% downside. The mean target is $159.07. This offers -5.25% upside. Belite Bio, Inc earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 10, 2025, missed forecasts by 22.64%. The prior quarter beat by 6.38%. Over the last six quarters, Apple has recorded several small beats. These include 10.71% in August 09, 2024.

Belite Bio, Inc (NASDAQ:BLTE) closed at $167.88 USD, losing -$9.70 (-5.46%) from the previous close of $177.58. The stock is currently mid-range between its 52-week high and low $49.00 and $200.00. With a market capitalization of about $6.30 billion, Belite Bio, Inc is classified as a mid-cap and shows lower-than-market volatility (beta ~-1.46). Key stats such as the average daily volume over the past year has been around 227.54 thousand shares, in line with its 52-week average. Headquartered in San Diego, CA, Belite Bio, Inc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Yu-Hsin Lin, the company employs approximately 25 people and listed since April 29, 2022. Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases.

Belite Bio, Inc trades at a P/E ratio of -92.11, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 20.97 reflecting a rich premium to book value. The P/FCF stands at 0.0, also below market averages. Compared to sector medians, Belite Bio, Inc P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Belite Bio, Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.61%, with price expected at $178.98 by March 17, 2026, within a range of $173.50 to $184.14 3-Month Outlook: Projected rise of 29.53%, reaching $217.46 by June 01, 2026, with a range of $216.03 to $219.08. 1-Year Outlook: Projected gain of 22.18%, with price at $205.12 by March 03, 2027, within a range of $195.73 to $213.30.

Belite Bio, Inc (NASDAQ:BLTE) shares are flat 0.03% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Belite Bio, Inc trading at a premium to the broader market with a P/E of -92.11. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $106.00, suggesting -36.86% downside. Our AI forecast model points to short-term strength (6.61% over two weeks), a medium-term rise (29.53% over three months), and a longer-term gain (22.18% over one year), with expected trading ranges indicating moderate volatility.